Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer

Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer

Show other versions (1)

<p align="LEFT">Buserelin is one of the first synthetic gonadotropin-releasing hormone agonists. The R.M. Fronshtein Clinic of Urology, I.M. Sechenov First Moscow State Medical University, has experience in using Buserelin depot in 32 patients with metastatic prostate cancer. The res...

Full description

Bibliographic Details
Main Authors:	L. M. Rapoport, Yu. L. Demidko
Format:	Article
Language:	Russian
Published:	ABV-press 2014-12-01
Series:	Андрология и генитальная хирургия
Subjects:	prostate cancer synthetic gonadotropin-releasing hormone agonists Buserelin depot
Online Access:	http://agx.abvpress.ru/index.php/jour/article/view/110

Similar Items

Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer
by: L. M. Rapoport, et al.
Published: (2014-12-01)

EVALUATION OF EFFICACY OF BUSERELIN-DEPO IN PATIENTS WITH LOCALLY ADVANCED AND METHASTATIC PROSTATE CANCER
by: S. V. MISHUGIN, et al.
Published: (2017-06-01)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
by: Feng Zhou, et al.
Published: (2016-01-01)

Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells
by: Kuan-Hao Tsui, et al.
Published: (2014-03-01)

Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
by: Min Jin Jeon, et al.
Published: (2021-09-01)

Short, semi-short or long GnRH agonist treatment regimens in women ICSI candidate; which is proper in
by: Popea Rezaeian, et al.
Published: (2016-09-01)

Effect of vaginal estriol use in total laparoscopic hysterectomy with gonadotropin-releasing hormone agonist therapy
by: Go Hirata, et al.
Published: (2018-01-01)

Aggressive angiomyxoma of the vulva: dramatic response to gonadotropin-releasing hormone agonist therapy
by: Azar Danesh, et al.
Published: (2007-08-01)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
by: Eun Jin Han, et al.
Published: (2013-09-01)

Use of a Gonadotropin-Releasing Hormone Agonist to Manage Perimenopausal Women With Symptomatic Uterine Myomas
by: Peng-Hui Wang, et al.
Published: (2009-06-01)

Vaginal Expulsion of a Submucosal Myoma During Treatment with Long-Acting Gonadotropin-Releasing Hormone Agonist
by: Lily Wen, et al.
Published: (2006-06-01)

Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
by: Hye Ryun Kim, et al.
Published: (2017-12-01)

Gonadotropin releasing hormone agonists: Expanding vistas
by: Navneet Magon
Published: (2011-01-01)

Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropin‐releasing hormone agonist for women undergoing fertility preservation
by: Yeon Hee Hong, et al.
Published: (2022-01-01)

Transcriptome profiling reveals superovulation with the gonadotropin-releasing hormone agonist trigger impaired embryo implantation in mice
by: Meng Li, et al.
Published: (2024-02-01)

Evaluation of dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin in improving oocyte maturity rates: A prospective randomized study
by: Nalini Mahajan, et al.
Published: (2016-01-01)

Comparison of the effect of gonadotropin-releasing hormone agonist dosage in girls with central precocious puberty
by: Shinyoung Jang, et al.
Published: (2023-02-01)

The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty
by: Jong Wan Yoon, et al.
Published: (2017-12-01)

Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
by: Liu YF, et al.
Published: (2021-02-01)

Effect of luteal phase support gonadotropin-releasing hormone agonist on the endometrial receptivity and outcomes of in vitro fertilization programs
by: E M Savelyeva, et al.
Published: (2016-06-01)

Effects of Secretoneurin and Gonadotropin-Releasing Hormone Agonist on the Spawning of Captive Greater Amberjack (<i>Seriola dumerili</i>)
by: Song Yanlong, et al.
Published: (2022-09-01)

Ovarian Cyst Formation Following Gonadotropin-Releasing Hormone-Agonist Administration Decreases the Oocyte Quality in IVF Cycles
by: Muammer Doğan, et al.
Published: (2012-06-01)

Functional Ovarian Cysts in Artificial Frozen-Thawed Embryo Transfer Cycles With Depot Gonadotropin-Releasing Hormone Agonist
by: Hui Ji, et al.
Published: (2022-04-01)

Comparison of gonadotropin-releasing hormone agonist with GnRH antagonist in polycystic ovary syndrome patients undergoing in vitro fertilization cycle: Retrospective analysis from a tertiary center and review of literature
by: Neeta Singh, et al.
Published: (2014-01-01)

Effect of gonadotropin-releasing hormone agonist treatment on near final height in girls with central precocious puberty and early puberty
by: Eun Hye Yang, et al.
Published: (2023-03-01)

HALF-DOSE DEPOT TRIPTORELIN COMPARABLE TO REDUCED DAILY BUSERELIN: A RANDOMIZED CLINICAL TRIAL
by: L. Safdarian, et al.
Published: (2007-12-01)

HALF-DOSE DEPOT TRIPTORELIN COMPARABLE TO REDUCED DAILY BUSERELIN: A RANDOMIZED CLINICAL TRIAL
by: L. Safdarian, et al.
Published: (2007-09-01)

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol
by: Behnaz Khani Rabati, et al.
Published: (2012-01-01)

Medical castration in the treatment of widespread cancers of the prostate. The role of buserelin
by: SV Mishugin, et al.
Published: (2014-12-01)

Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty
by: Ahmet Anik, et al.
Published: (2015-01-01)

Risk factors for empty follicle syndrome in assisted reproductive technology with gonadotropin‐releasing hormone agonist trigger
by: Daichi Inoue, et al.
Published: (2023-01-01)

No significant long-term complications from inadvertent exposure to gonadotropin-releasing hormone agonist during early pregnancy in mothers and offspring: a retrospective analysis
by: Huan Wu, et al.
Published: (2021-03-01)

Comparison of the clinical outcome of frozen-thawed embryo transfer with and without pretreatment with a gonadotropin-releasing hormone agonist
by: Jieun Kang, et al.
Published: (2018-07-01)

Prevalence of idiopathic scoliosis in girls with central precocious puberty: effect of a gonadotropin-releasing hormone agonist
by: Lindsey Yoojin Chung, et al.
Published: (2020-06-01)

EQUINOXE study: Impact of relational cohesion and sexuality on the quality of life of patients treated with gonadotropin‐releasing hormone agonist for prostate cancer
by: Stéphane Droupy, et al.
Published: (2022-01-01)

Gonadotropin releasing hormone antagonist protocol brings about more available embryos than agonist long protocol
by: ZHAO Shan-ke, FU Yao, CHU Da-peng, FU Lei, HAN Shuo, BAI Xue-yan, LI Yuan, ZHOU Wen-hui
Published: (2022-03-01)

Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer
by: L. K. Ovchinnikova, et al.
Published: (2019-06-01)

Progress and Challenges in the Search for the Mechanisms of Pulsatile Gonadotropin-Releasing Hormone Secretion
by: Stephanie Constantin
Published: (2017-07-01)

Gonadotropin-releasing hormone agonist combined with hormone replacement therapy does not improve the reproductive outcomes of frozen-thawed embryo transfer cycle in elderly patients: a retrospective study
by: Mei Dong, et al.
Published: (2020-07-01)

Effects of gonadotropin-releasing hormone agonist treatment on final adult height in boys with idiopathic central precocious puberty
by: Ah Young Cho, et al.
Published: (2021-12-01)